Current trends in inflammatory bowel disease: the natural history

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Current trends in inflammatory bowel disease : the natural history. / Langholz, Ebbe.

In: Therapeutic Advances in Gastroenterology, Vol. 3, No. 2, 03.2010, p. 77-86.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Langholz, E 2010, 'Current trends in inflammatory bowel disease: the natural history', Therapeutic Advances in Gastroenterology, vol. 3, no. 2, pp. 77-86. https://doi.org/10.1177/1756283X10361304

APA

Langholz, E. (2010). Current trends in inflammatory bowel disease: the natural history. Therapeutic Advances in Gastroenterology, 3(2), 77-86. https://doi.org/10.1177/1756283X10361304

Vancouver

Langholz E. Current trends in inflammatory bowel disease: the natural history. Therapeutic Advances in Gastroenterology. 2010 Mar;3(2):77-86. https://doi.org/10.1177/1756283X10361304

Author

Langholz, Ebbe. / Current trends in inflammatory bowel disease : the natural history. In: Therapeutic Advances in Gastroenterology. 2010 ; Vol. 3, No. 2. pp. 77-86.

Bibtex

@article{99ebb293b74a4f9082d19ada3338528e,
title = "Current trends in inflammatory bowel disease: the natural history",
abstract = "The description of the prognosis of inflammatory bowel disease (IBD) is based on systematic follow-up of population-based cohorts. A steady increase in incidence of IBD has occurred. The distribution of ulcerative colitis (UC) is fairly uniform with a preponderance of left-sided disease. One-third of Crohn's disease (CD) patients present with colonic disease, one-third with ileocolonic disease and one-third with small bowel disease. IBD is associated with extra-intestinal manifestations (EIMs) in up to 36% of patients. Uveitis and episcleritis are the most common. The cumulative probability of a relapsing course in UC is 90% after 25 years. In CD disease behaviour varies substantially with time. At diagnosis behaviour is inflammatory in 70% of patients. At follow-up there is a change to either stricturing or penetrating disease. Most patients with CD will eventually require surgery. Risk factors for CD recurrence after surgery include penetrating/fistulizing disease behaviour, young age, short duration of disease before first surgery and ileocolonic disease. The incidence of colorectal cancer (CRC) in UC seems to be decreasing. The risk of CRC in CD seems to be equivalent to the risk in UC. Patients with small bowel CD are also at increased risk of small bowel adenocarcinoma. CD is associated with a mortality rate 20-70% higher than expected, whereas mortality in UC is equivalent to that of the general population. The improved prognosis of IBD, especially UC, could be due to a chemopreventive effect of the medications used. Further studies are needed to develop the best strategy for the reduction of mortality and cancer risk in IBD.",
author = "Ebbe Langholz",
year = "2010",
month = mar,
doi = "10.1177/1756283X10361304",
language = "English",
volume = "3",
pages = "77--86",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications",
number = "2",

}

RIS

TY - JOUR

T1 - Current trends in inflammatory bowel disease

T2 - the natural history

AU - Langholz, Ebbe

PY - 2010/3

Y1 - 2010/3

N2 - The description of the prognosis of inflammatory bowel disease (IBD) is based on systematic follow-up of population-based cohorts. A steady increase in incidence of IBD has occurred. The distribution of ulcerative colitis (UC) is fairly uniform with a preponderance of left-sided disease. One-third of Crohn's disease (CD) patients present with colonic disease, one-third with ileocolonic disease and one-third with small bowel disease. IBD is associated with extra-intestinal manifestations (EIMs) in up to 36% of patients. Uveitis and episcleritis are the most common. The cumulative probability of a relapsing course in UC is 90% after 25 years. In CD disease behaviour varies substantially with time. At diagnosis behaviour is inflammatory in 70% of patients. At follow-up there is a change to either stricturing or penetrating disease. Most patients with CD will eventually require surgery. Risk factors for CD recurrence after surgery include penetrating/fistulizing disease behaviour, young age, short duration of disease before first surgery and ileocolonic disease. The incidence of colorectal cancer (CRC) in UC seems to be decreasing. The risk of CRC in CD seems to be equivalent to the risk in UC. Patients with small bowel CD are also at increased risk of small bowel adenocarcinoma. CD is associated with a mortality rate 20-70% higher than expected, whereas mortality in UC is equivalent to that of the general population. The improved prognosis of IBD, especially UC, could be due to a chemopreventive effect of the medications used. Further studies are needed to develop the best strategy for the reduction of mortality and cancer risk in IBD.

AB - The description of the prognosis of inflammatory bowel disease (IBD) is based on systematic follow-up of population-based cohorts. A steady increase in incidence of IBD has occurred. The distribution of ulcerative colitis (UC) is fairly uniform with a preponderance of left-sided disease. One-third of Crohn's disease (CD) patients present with colonic disease, one-third with ileocolonic disease and one-third with small bowel disease. IBD is associated with extra-intestinal manifestations (EIMs) in up to 36% of patients. Uveitis and episcleritis are the most common. The cumulative probability of a relapsing course in UC is 90% after 25 years. In CD disease behaviour varies substantially with time. At diagnosis behaviour is inflammatory in 70% of patients. At follow-up there is a change to either stricturing or penetrating disease. Most patients with CD will eventually require surgery. Risk factors for CD recurrence after surgery include penetrating/fistulizing disease behaviour, young age, short duration of disease before first surgery and ileocolonic disease. The incidence of colorectal cancer (CRC) in UC seems to be decreasing. The risk of CRC in CD seems to be equivalent to the risk in UC. Patients with small bowel CD are also at increased risk of small bowel adenocarcinoma. CD is associated with a mortality rate 20-70% higher than expected, whereas mortality in UC is equivalent to that of the general population. The improved prognosis of IBD, especially UC, could be due to a chemopreventive effect of the medications used. Further studies are needed to develop the best strategy for the reduction of mortality and cancer risk in IBD.

U2 - 10.1177/1756283X10361304

DO - 10.1177/1756283X10361304

M3 - Journal article

C2 - 21180592

VL - 3

SP - 77

EP - 86

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 2

ER -

ID: 219528815